| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03143998 Details | 2017-11-09 Interventional | 4 | 0 | Elbasvir-grazop… Grazoprevir Hepatitis Hepatitis A Hepatitis C Hepatitis C, Ch… | Business reasons - | |||
| NCT02840591 Details | 2017-11-09 Interventional | 4 | 0 | Cytidine Diphos… Delirium | Stopped the study due to feasibility issues, no enrollment has taken place. - | |||
| NCT02936492 Details | 2017-11-08 Interventional | 1 | 32 | Clobetasol Psoriasis | - - | |||
| NCT02510248 Details | 2017-11-08 Interventional | 1 | 42 | 1-2-isopropoxy-… Hepatitis C Hepatitis C, Ch… Chronic Hepatit… | - - | |||
| NCT01005459 Details | 2017-11-08 Interventional | 4 | 46 | Bupivacaine Tetracaine Labor Pain | feasibility /drug availability issues - No study drug sources available - | |||
| NCT00550420 Details | 2017-11-08 Interventional | 3 | 331 | Rosiglitazone Alzheimer Disea… Alzheimer's Dis… | Based on preliminary parent study results The study was early terminated on 12 February 2009 because RSG XR as monotherapy in Alzheimer's disease failed to demonstrate efficacy. | |||
| NCT03024060 Details | 2017-11-07 Interventional | 3 | 0 | Aminolevulinic … Keratosis Keratosis, Acti… Actinic Keratos… | Study withdrawn due to corporate business decision - | |||
| NCT00471237 Details | 2017-11-07 Interventional | 2 | 564 | Alendronate Teriparatide Osteoporosis | Terminated for futility by sponsor after a pre-planned interim review of data The study was terminated for futility in a phased manner by the sponsor on 25-Sep-2008 once the results of a planned 6-month interim analysis were available. | |||
| NCT03219983 Details | 2017-11-06 Interventional | 4 | 22 | Bupivacaine Ropivacaine Arthritis Glenohumeral Ar… Total Shoulder … | - - | |||
| NCT02642523 Details | 2017-11-06 Interventional | 1 | 0 | Insulin Insulin, Globin… Natriuretic Pep… Hyperinsulinism Obesity Hyperinsulinemi… | Preliminary data run on rat samples showed that this study question and design would not
produce conclusive results. The PI decided not to carry out the study. - | |||
| NCT02221947 Details | 2017-11-06 Interventional | 1/2 | 9 | Bryostatin 1 Alzheimer Disea… Alzheimer's Dis… | Part 2 of study replaced by NTRP-101-202, assessing 3 doses of bryostatin. - | |||
| NCT01362205 Details | 2017-11-06 Interventional | 4 | 49 | Dexmedetomidine Alcohol Withdra… Delirium Substance Withd… Alcohol Withdra… Alcohol Withdra… Alcohol Withdra… | DSMB recommendation for slow enrollment Early termination due to slow enrollment leading to small numbers of subjects analyzed | |||
| NCT00690911 Details | 2017-11-06 Interventional | 2 | 0 | Adalimumab Sarcoidosis | Dr. Jorizzo has decided to withdraw from this study due to the time it is taking to get the
study started. - | |||
| NCT00611455 Details | 2017-11-06 Interventional | 3 | 265 | Ofatumumab Arthritis Arthritis, Rheu… | Ofatumumab IV trials in RA were prematurely terminated because GSK refocused clinical
development of autoimmune indications on the subcutaneous delivery. - | |||
| NCT00400205 Details | 2017-11-06 Interventional | 2 | [1 Refs] | 14 | Docetaxel Fluorouracil Carcinoma Carcinoma, Squa… Mouth Neoplasms Oral Cancer Squamous Cell C… | Safety reasons - | ||
| NCT03095547 Details | 2017-11-01 Interventional | 1 | 0 | Cyclosporine Cyclosporins Olorofim Pantoprazole Posaconazole Tacrolimus Aspergillosis Invasive Asperg… | study no longer required in current format - | |||
| NCT03076905 Details | 2017-11-01 Interventional | 1 | 0 | Olorofim Aspergillosis Invasive Asperg… | study no longer required in current format - | |||
| NCT02999906 Details | 2017-11-01 Interventional | 3 | 0 | Treprostinil Familial Primar… Hypertension Pulmonary Arter… | For business reasons. - | |||
| NCT02433483 Details | 2017-11-01 Interventional | 2 | 4 | Cytarabine Hydrocortisone Methotrexate Hematologic Neo… Leukemia, Myelo… Myelodysplastic… Preleukemia Acute Myeloid L… Myelodysplastic… | The study was closed due to poor accrual and because of competing protocols. This study was terminated in May 2017 due to poor accrual and because of competing protocols. | |||
| NCT01666600 Details | 2017-11-01 Interventional | 1/2 | 63 | Nintedanib Glioblastoma Glioblastoma Mu… | Interim Analysis for Feasibility - |